Thread: Future treatments
View Single Post
Old 08-06-2014, 08:53 AM
Jenn220 Jenn220 is offline
Junior Member
  
Join Date: May 2009
Posts: 18
15 yr Member
Jenn220 Jenn220 is offline
Junior Member
 
Join Date: May 2009
Posts: 18
15 yr Member
Default
Quote:
Originally Posted by Panorama View Post
You might be right . . .
The European Commission (EC) has granted orphan drug designation (ODD) to Alexion Pharmaceuticals' Soliris (eculizumab), a first-in-class terminal complement inhibitor, to treat patients with Myasthenia Gravis (MG).
http://regulatoryaffairs.pharmaceuti...040814-4334013

http://www.marketwatch.com/story/eur...-mg-2014-08-01

-Mark-
No need to move - the FDA granted orphan drug status to eculizumab for MG in the US in June:

http://www.marketwatch.com/story/fda...-mg-2014-06-17

And, there is a clinical trial underway to test the drug in MG. Most of the trial sites that have opened so far are in the US, with one in Canada and two in Japan:

http://www.clinicaltrials.gov/ct2/sh...thenia&rank=21
Jenn220 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
Panorama (08-06-2014)